- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04783922
An Update on Intracerebral Hemorrhage
An Update on Intracerebral Hemorrhage - A Cohort Study
The intracerebral hemorrhage study is a multicenter , combination of prospective and retrospective observational cohort study led by Dr. Muhammad Junaid Akram, PhD scholar at Chongqing Medical University. Prof Dr. Qi Li will be the senior consultant for the study. The study will be focusing on natural history, epidemiological , radiological, rehabilitative and clinical aspects as well as the effect of various treatments on the hemorrhagic patients.
The study related data of the patients diagnosed with intracerebral hemorrhage will be collected in prospective and retrospective ways. The prognostic data for the patients will be assembled and collected via using different outcome measures at different points of time.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Muhammad Junaid Akram, DPT, MS-NMPT
- Telefonnummer: 0092-335-1402214
- E-post: drjunaidmalik2@gmail.com
Studer Kontakt Backup
- Navn: Muhammad Junaid Akram
- Telefonnummer: 0092-335-1402214
- E-post: drjunaidmalik2@gmail.com
Studiesteder
-
-
-
Islamabad, Pakistan, 46000
- Rekruttering
- Shifa Tameer E Millat University
-
Ta kontakt med:
- Muhammad Junaid Akram, PhD*
- E-post: drjunaidmalik2@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age > 18 years Patients willing to participate via signing a consent form' Patients diagnosed with CT-Confirmed spontaneous intracerebral hemorrhage (ICH) Patients willing to participate in the follow up assessment
Exclusion Criteria:
- Not willing to participate Secondary ICH to hemorrhagic infarction or tumor bleeding etc. Traumatic ICH
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Benign Hematoma
Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand.
|
Malignant Hematoma
Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
hematomvolumvekst etter 24 timer
Tidsramme: 24 timer
|
For å vurdere tidlig hematomvolumvekst etter 24 timer
|
24 timer
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Functional outcome at 3 months assessed by modified Rankin Scale
Tidsramme: 3 months
|
Assess functional outcome at 3 months by using mRS
|
3 months
|
Early neurological deterioration assessed by NIHSS score at 24 hours
Tidsramme: 24 hours
|
To assess early neurological deterioration by using NIHSS score at 24 hours
|
24 hours
|
Early neurological deterioration assessed by NIHSS score at 48 hours
Tidsramme: 48 hours
|
To assess early neurological deterioration by using NIHSS score at 48 hours
|
48 hours
|
Early neurological deterioration assessed by NIHSS score at 72 hours
Tidsramme: 72 hours
|
To assess early neurological deterioration by using NIHSS score at 72 hours
|
72 hours
|
Perihematomal edema volume measurement at 24 hours
Tidsramme: 24 hours
|
To measure the perihematomal edema volume growth at 24 hours
|
24 hours
|
Perihematomal edema volume measurement at 48 hours
Tidsramme: 48 hours
|
To measure the perihematomal edema volume growth at 48 hours
|
48 hours
|
Perihematomal edema volume measurement at 72 hours
Tidsramme: 72 hours
|
To measure the perihematomal edema volume growth at 72 hours
|
72 hours
|
Intraventricular hemorrhage growth
Tidsramme: 24 hours
|
To assess the presence of IVH at 24 hours
|
24 hours
|
Major thrombotic events
Tidsramme: 2 weeks
|
To assess the thrombotic events 2 weeks after admission
|
2 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Muhammad Junaid Akram, DPT, MS-NMPT, Chongqing Medical University, Chongqing / Shifa Tameer e Millat University, Islamabad
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB-Approval- Submitted
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .